Telemedicine in French Memory Clinics During the COVID-19 Pandemic.

Alzheimer’s disease COVID-19 psychoactive drugs telemedicine treatments in dementia

Journal

Journal of Alzheimer's disease : JAD
ISSN: 1875-8908
Titre abrégé: J Alzheimers Dis
Pays: Netherlands
ID NLM: 9814863

Informations de publication

Date de publication:
2022
Historique:
pubmed: 3 1 2022
medline: 2 4 2022
entrez: 2 1 2022
Statut: ppublish

Résumé

This multicenter study was conducted in French memory clinics during the first COVID-2019 lockdown (March-May 2020). The objective was to evaluate the effect of a telemedicine consultation on treatment modification in dementia care. Among 874 patients who had a telemedicine consultation, 103 (10.7%) had treatment modifications, in particular those living with a relative or diagnosed with Alzheimer's disease. A control group of patients referred March-May 2019 was also included. Treatment modification rate was similar between periods with an adjusted percentage difference of -4% (p = 0.27). Telemedicine consultations allowed treatment modifications with only a minor short-term negative impact on therapeutic strategies.

Identifiants

pubmed: 34974434
pii: JAD215459
doi: 10.3233/JAD-215459
doi:

Types de publication

Journal Article Multicenter Study

Langues

eng

Sous-ensembles de citation

IM

Pagination

525-530

Auteurs

Alexandre Morin (A)

CHU Rouen, Department of Neurology and CIC-CRB1404, Rouen, France.

Thibaut Pressat-Laffouilhere (T)

CHU Rouen, Department of Biostatistics, Rouen, France.

Marie Sarazin (M)

Department of Neurology of Memory and Language, GHU Paris Psychiatry and Neurosciences, Hôpital Sainte Anne, Paris, France.
Université de Paris, Paris, France.
Université Paris-Saclay, BioMaps, CEA, CNRS, Inserm, Orsay, France.

Julien Lagarde (J)

Department of Neurology of Memory and Language, GHU Paris Psychiatry and Neurosciences, Hôpital Sainte Anne, Paris, France.
Université de Paris, Paris, France.
Université Paris-Saclay, BioMaps, CEA, CNRS, Inserm, Orsay, France.

Carole Roue-Jagot (C)

Department of Neurology of Memory and Language, GHU Paris Psychiatry and Neurosciences, Hôpital Sainte Anne, Paris, France.
Université de Paris, Paris, France.
Université Paris-Saclay, BioMaps, CEA, CNRS, Inserm, Orsay, France.

Pauline Olivieri (P)

Department of Neurology of Memory and Language, GHU Paris Psychiatry and Neurosciences, Hôpital Sainte Anne, Paris, France.
Université de Paris, Paris, France.
Université Paris-Saclay, BioMaps, CEA, CNRS, Inserm, Orsay, France.

Claire Paquet (C)

Université de Paris, Cognitive Neurology Center, Lariboisiere - Fernand Widal Hospital, APHP, Paris, France.

Emmanuel Cognat (E)

Université de Paris, Cognitive Neurology Center, Lariboisiere - Fernand Widal Hospital, APHP, Paris, France.

Julien Dumurgier (J)

Université de Paris, Cognitive Neurology Center, Lariboisiere - Fernand Widal Hospital, APHP, Paris, France.

Florence Pasquier (F)

Department of Neurology, Lille University Hospital, Lille, France.

Thibaut Lebouvier (T)

Department of Neurology, Lille University Hospital, Lille, France.

Matthieu Ceccaldi (M)

Department of Neurology, Marseille University Hospital, APHM, Marseille, France.

Olivier Godefroy (O)

Department of Neurology, Amiens University Hospital, Amiens, France.

Olivier Martinaud (O)

Department of Neurology, Caen University Hospital, Caen, France.
Normandie UNIV, UNICAEN, PSL Research University, EPHE, INSERM, CHU de Caen, Neuropsychologie et Imagerie de la mémoire humaine, Caen, France.

Julien Grosjean (J)

Department of Biomedical Informatics, Rouen University Hospital, Rouen, France.
LIMICS, INSERM U1142, Sorbonne Université, Paris, France.

Aline Zarea (A)

CHU Rouen, Department of Neurology and CIC-CRB1404, Rouen, France.
Normandie Univ, UNIROUEN, Inserm U1245 and CNR-MAJ, Normandy Center for Genomic and Personalized Medicine, Rouen, France.

David Maltête (D)

CHU Rouen, Department of Neurology and CIC-CRB1404, Rouen, France.

David Wallon (D)

CHU Rouen, Department of Neurology and CIC-CRB1404, Rouen, France.
Normandie Univ, UNIROUEN, Inserm U1245 and CNR-MAJ, Normandy Center for Genomic and Personalized Medicine, Rouen, France.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH